Literature DB >> 9157140

Comparison of agar dilution, broth microdilution, disk diffusion, E-test, and BACTEC radiometric methods for antimicrobial susceptibility testing of clinical isolates of the Nocardia asteroides complex.

A Ambaye1, P C Kohner, P C Wollan, K L Roberts, G D Roberts, F R Cockerill.   

Abstract

An evaluation was undertaken to determine the optimal method for the in vitro susceptibility testing of 26 Nocardia asteroides complex isolates to the following antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, erythromycin, imipenem, minocycline, and trimethoprim-sulfamethoxazole. Five testing methods were studied including the agar dilution, broth microdilution, and disk diffusion methods, the epsilometer test (E-test), and the BACTEC radiometric method. Results for each antimicrobial agent and each testing method were interpreted as indicating susceptibility, intermediate susceptibility, or resistance according to current guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) for bacteria that grow aerobically and were then compared to a "gold standard" susceptibility test result. The gold standard result for each Nocardia isolate was established by a consensus of the results of the majority of testing methods used in the study. When the results were combined for all antimicrobial agents tested against all Nocardia isolates by all methods, the BACTEC radiometric method produced the highest level of agreement (97.9%) with the consensus results and had the fewest very major (n = 1), major (n = 2), and minor (n = 2) errors. In contrast, the results of the agar dilution method were in least agreement (93.2%) with the consensus results, and this method also produced the most very major (n = 8), major (n = 4), and, along with the disk diffusion method, minor (n = 6) errors. For all test methods, interpretive errors were most frequent when testing ampicillin or amoxicillin-clavulanate. Moreover, for all Nocardia nova isolates tested, ampicillin susceptibility results by any of the testing methods were not in agreement with the results of testing for beta-lactamase by the nitrocefin (Cefinase) disk method. We conclude that among the methods evaluated, the BACTEC radiometric method appeared to be the best for determining the in vitro susceptibilities of members of the N. asteroides complex to a panel of nine antimicrobial agents. However, none of the test methods, including the BACTEC method, accurately predicted the ampicillin resistance of the N. nova isolates tested, all of which produced beta-lactamase. Presuming that this beta-lactamase hydrolyzes ampicillin, this disparity may relate to the NCCLS breakpoints that were used, which may require modification for this antimicrobial agent when tested against N. nova isolates.

Entities:  

Mesh:

Year:  1997        PMID: 9157140      PMCID: PMC229688          DOI: 10.1128/jcm.35.4.847-852.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Antimicrobial susceptibility patterns of Nocardia asteroides.

Authors:  R J Wallace; L C Steele; G Sumter; J M Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  Disk diffusion susceptibility testing of Nocardia species.

Authors:  R J Wallace; E J Septimus; D M Musher; R R Martin
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

3.  Comparative evaluation of the E test for susceptibility testing of Nocardia species.

Authors:  J R Biehle; S J Cavalieri; M A Saubolle; L J Getsinger
Journal:  Diagn Microbiol Infect Dis       Date:  1994-06       Impact factor: 2.803

4.  In vitro susceptibility of Nocardia asteroides to 25 antimicrobial agents.

Authors:  D H Dewsnup; D N Wright
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Trimethoprim/sulfamethoxazole-resistant Nocardia asteroides causing multiple hepatic abscesses. Successful treatment with ampicillin, amikacin, and limited computed tomography-guided needle aspiration.

Authors:  F R Cockerill; R S Edson; G D Roberts; J C Waldorf
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

6.  Beta-lactamase production and resistance to beta-lactam antibiotics in Nocardia.

Authors:  R J Wallace; P Vance; A Weissfeld; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

7.  Clinical and laboratory features of Nocardia nova.

Authors:  R J Wallace; B A Brown; M Tsukamura; J M Brown; G O Onyi
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

8.  Minocycline treatment of pulmonary nocardiosis.

Authors:  E A Petersen; M L Nash; R B Mammana; J G Copeland
Journal:  JAMA       Date:  1983-08-19       Impact factor: 56.272

9.  In-vitro susceptibility of Nocardia asteroides to 21 beta-lactam antibiotics, in combination with three beta-lactamase inhibitors, and its relationship to the beta-lactamase content.

Authors:  M D Kitzis; L Gutmann; J F Acar
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

10.  Activity of antimicrobial drugs evaluated by agar dilution and radiometric methods against strains of Nocardia asteroides isolated in Italy from immunocompromised patients.

Authors:  F Scopetti; E Iona; L Fattorini; A Goglio; N Franceschini; G Amicosante; G Orefici
Journal:  J Chemother       Date:  1994-02       Impact factor: 1.714

View more
  26 in total

1.  Biochemical-genetic analysis and distribution of FAR-1, a class A beta-lactamase from Nocardia farcinica.

Authors:  F Laurent; L Poirel; T Naas; E B Chaibi; R Labia; P Boiron; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Nocardiosis: review of clinical and laboratory experience.

Authors:  Michael A Saubolle; Den Sussland
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 3.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

4.  Successful treatment of a disseminated Nocardia brasiliensis infection.

Authors:  L C Smeets; M A van Agtmael; E R van der Vorm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

5.  Nocardia pseudobrasiliensis as an emerging cause of opportunistic infection after allogeneic hematopoietic stem cell transplantation.

Authors:  David Lebeaux; Fanny Lanternier; Nicolas Degand; Emilie Catherinot; Isabelle Podglajen; Marie-Thérèse Rubio; Felipe Suarez; Marc Lecuit; Jean-Luc Mainardi; Olivier Lortholary
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

6.  Pneumonia involving Aspergillus and Rhizopus spp. after a near-drowning incident with subsequent Nocardia cyriacigeorgici and N. farcinica coinfection as a late complication.

Authors:  A P van Dam; M T C Pruijm; B I J Harinck; L B S Gelinck; E J Kuijper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

7.  Nocardia veterana, a new emerging pathogen.

Authors:  Sudha Pottumarthy; Ajit P Limaye; Jennifer L Prentice; Yolanda B Houze; Susan R Swanzy; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

8.  Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis.

Authors:  Lisa R McTaggart; Jennifer Doucet; Maria Witkowska; Susan E Richardson
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

9.  In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.

Authors:  G Hansen; S Swanzy; R Gupta; B Cookson; A P Limaye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267

10.  Emergence of co-trimoxazole resistant Nocardia brasiliensis causing fatal pneumonia.

Authors:  Vineeta Khare; Prashant Gupta; D Himanshu; Deepak Kumar
Journal:  BMJ Case Rep       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.